Sorry you are afraid of facts. Let's get this straight. Your position is that the company announced a 2 year licensing agreement to its public shareholders, but never closed the deal? That's what it sounds like you're claiming. Can you back that claim up with the public filings? I can show you the truth if you're interested and not too afraid.
"Effective February 2, 2022, the Company acquired the option to purchase U.S. Patent No. 9,783,432B (the “Patent”), covering technology used in enhancing the capability of water to hold significantly larger amounts of oxygen. Since June 6, 2022, we entered into a services agreement with Wildpack Beverages in Las Vegas, Nevada to co-pack a pilot run (1333 cases) of this Product. However, since technical problems prevented completion of the planned pilot run, we are still working to rectify these issues and explore how to deploy the technology." Ummmmm, pathetic.
How about this nugget from the last public quarterly report:
"During July and early August, The REG A filed and as amended in November 2022 for 200,000,000 common shares at $0.001 were fully subscribed. This provides the Company with the liquidity to pursue further research into its lead products: Pluripain® , SleepEZ™ and Primilungs™ and move the Company’s testing, development and marketing programs forward. The Company is also in discussion with marketing specialists in expanding its footprint on the Amazon market place now that the RegA has been fully subscribed and provide the necessary funding for more intensive marketing efforts. Since the appointment of FCBTherapy as its exclusive Distributor, LiveStock impact is withdrawing from its own websale and is encouraged with the first initial wholesale order from FCBTherapy is over $9000 which is double the last 6 months gross sales."
You understand that, yes? They got a HUGE wholesale order of $9,000 for their equine products. And that was DOUBLE what they made in the past 6 months! How this company has a market cap over $50,000 is the true mystery.
Let's try this. You seem very wise and an experienced investor. Can you help explain this public company statement from the quarterly report with your analysis why BDPT is a great investment:
"Since the latter part of March, the Company has started to explore the Botanical Drugs sphere. We acquires the non exclusive licenses from Dr. Yaguang Liu, LY Research for Glucose Management, Eye Health due to Myopia and Presbyopia and a resveratrol product. Dr Liu has had over 40 years of research and development in the Botanical Drugs area. We are exploring the opportunities in deploying these patented products for nutraceutical use for human and animal initially.
While we continue to investigate and acquire nutraceutical products for humans and animals, all of our current activities are reliant on marketing and distributing products developed and owned by others. Currently, other than the two equine formulations where we have the exclusive marketing rights, we do not own the formulations for our key products and manufacture and market them under an agreement with the developer that requires payment of a royalty and a license agreement. We are negotiating towards the acquisition of some of these formulations.
We are reliant on direct web sales of the nutraceutical lines for humans and the All-in-One animal products for revenues, none of which has produced any significant revenue yet. Because of this, we are now exploring the wholesale and affiliate markets for their sales. We have very limited experience in marketing and have yet to develop reliable sales expectations and forecasting."
C'mon, don't worry about fear(mongering). Help us understand.
News 
Market Data 
Discover 
AI
